IL15 and neoplasm: The antitumor effect of the B16-LX/IL(15 + 7) vaccine was tumor-specific, as the EL4-LX/IL(15 + 7) vaccine (i.e., irradiated EL-4 tumor cells loaded with LX/IL(15 + 7)) did not inhibit antigenically unrelated B16-F10 tumor growth [31].